Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T01:29:52.725Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of life in a sample of schizophrenic patients with and without metabolic syndrome

Published online by Cambridge University Press:  13 July 2010

Tomás Sánchez-Araña Moreno ,
Sergio Ruiz-Doblado ,
José Luis Hernández-Fleta ,
Ramon Touriño-Gonzalez  and
Petra León-Pérez
Tomás Sánchez-Araña Moreno
Affiliation:
Psychiatric Services, Puerto Real University Hospital, Cadiz, Spain
Sergio Ruiz-Doblado*
Affiliation:
Chairman, Psychiatric and Mental Health Services, Osuna Hospital, Seville, Spain
José Luis Hernández-Fleta
Affiliation:
Psychiatric Department, Grand Canary Dr Negrin University Hospital & School of Medicine, Canary Islands, Spain
Ramon Touriño-Gonzalez
Affiliation:
Psychiatric Department, Grand Canary Dr Negrin University Hospital & School of Medicine, Canary Islands, Spain
Petra León-Pérez
Affiliation:
Psychiatric Department, Grand Canary Dr Negrin University Hospital & School of Medicine, Canary Islands, Spain
*
Correspondence to: Sergio Ruiz-Doblado, Servicio de Psiquiatra, Hospital de Osuna, Avda. Constitución, 2, Osuna, Sevilla 41640, Spain. Tel: +34 955077257; Fax: +34 955077257; E-mail: [email protected]
Get access

Abstract

Introduction: Quality of life is an important measure of results in psychiatry in general, and in the treatment of schizophrenia in particular. The metabolic syndrome has a strong prevalence in schizophrenia, and can have an impact on quality of life.

Objective: To compare the perceived quality of life of a sample of schizophrenic patients with and without metabolic syndrome.

Methods: Cross-sectional observational study, including 136 patients (49 with metabolic syndrome) admitted in 2004 to a short-term hospitalization psychiatric unit with a diagnosis of schizophrenia or schizoaffective disorder validated using the SCID-I. Metabolic syndrome defined according to NCEP-ATP III criteria. Quality of life assessed using the EuroQol 5D. Simple associative, and multivariate analysis (logistic regression) were performed.

Results: In the schizophrenic patients studied, metabolic syndrome is associated with age (p = 0.035), pension beneficiary (p = 0.005), antipsychotics treatment (p = 0.017), years of evolution (p = 0.008), and also with a lower score on the EuroQol 5D ‘health state today’ (p = 0.035) and ‘mobility’ (p = 0.011) dimensions. Multivariate analysis (logistic regression) shows that quality of life is mainly associated with age (OR = 3.2), metabolic syndrome (OR = 2.6) and mobility problems (OR = 2).

Conclusion: When treating schizophrenic patients, we should take into account comorbidity with metabolic syndrome, since the latter, in addition to representing a significant cardiovascular risk factor, can also affect, added to treatment issues, illness factors and other social and environmental variables, the patient’s quality of life.

Keywords

Schizophreniametabolic syndromequality of life
Type
Original Article
Information
Journal of Psychiatric Intensive Care , Volume 6 , Issue 2 , December 2010 , pp. 101 - 108
Copyright
Copyright © NAPICU 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Awad, A.G. and Voruganti, L.N. (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 18(13): 877–893.CrossRefGoogle ScholarPubMed
Barcia, D., Morcillo, L. and Borgoñós, E. (1995) Esquizofrenia: calidad de vida y formas clínicas. Anales de Psiquiatría. 11(3): 81–87.Google Scholar
Bengtsson-Tops, A. and Hansson, L. (1999) Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics. European Psychiatry. 14(5): 256–263.CrossRefGoogle ScholarPubMed
Caron, J., Mercier, C., Diaz, P and Martin, A. (2005) Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Research. 137(3): 203–213.CrossRefGoogle ScholarPubMed
Dossenbach, M., Hodge, A., Anders, M., Molnár, B., Peciukaitiene, D., Krupka-Matuszczyk, I., Tatu, M., Bondar, V., Pecenak, J., Gorjanc, T. and McBride, M. (2005) Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. International Journal of Neuropsychopharmacology. 8(2): 195–201.CrossRefGoogle ScholarPubMed
EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 16(3): 199–208.CrossRefGoogle Scholar
Faulkner, G., Cohn, T., Remington, G. and Irving, H. (2007) Body mass index, waist circunsference and quality of life in individuals with schizophrenia. Schizophrenia Research. 90(1): 174–178. doi: 10.1016/j.schres.2006.10.009CrossRefGoogle ScholarPubMed
First, M.B., Spitzer, R.L., Gibbon, M. and Williams, J.B.W. (1997) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician version (SCID-CV). Washington DC: American Psychiatric Publishing, Inc.Google Scholar
Glynn, S.M., Marder, S.R., Liberman, R.P., Blair, K., Wirshing, W.C., Wirshing, D.A., Ross, D. and Mintz, J. (2002). Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. American Journal of Psychiatry. 159(5): 829–837.CrossRefGoogle ScholarPubMed
Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B. Jr, Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C. Jr and Stone, N.J. Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology. 44(3): 720–732.CrossRefGoogle ScholarPubMed
Hofer, A., Baumgartner, S., Edlinger, M., Hummer, M., Kemmler, G., Rettenbacher, M.A., Schweigkofler, H., Schwitzer, J. and Fleischhacker, W.W. (2005) Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry. 20(5–6): 386–394.CrossRefGoogle ScholarPubMed
Kastchnihg, H. (2000) Componentes de la calidad de vida. Bienestar/satisfacción subjetivos, estado funcional, factores contextuales. In: Kastchnig, H., Freeman, H., Sartorius, N. (eds). Calidad de Vida en los Trastornos Mentales. Barcelona: Masson. pp. 9–10.Google Scholar
Kilian, R. and Angermeyer, M.C. (2005) The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Quality of Life Research. 14(5): 1275–1289.CrossRefGoogle Scholar
Lehman, A.F. (2000) Instrumentos para medir la calidad de vida en los trastornos mentales. In: Katsching, H., Freeman, H., Sartorius, N. (eds). Calidad de Vida en los Trastornos Mentales. Barcelona: Masson. pp 77–92.Google Scholar
Meyer, J.M., Nasrallah, H.A., McEvoy, J.P., Goff, D.C., Davis, S.M., Chakos, M., Patel, J., Keefe, R.S.E., Stroup, T.S. and Lieberman, J.A. (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 80(1): 9–18.CrossRefGoogle ScholarPubMed
Minguez, L., González, E., Alonso, F., Sanguino, R.M. and García, Y. (2005) Efectos adversos de los antipsicóticos y calidad de vida. Actas Españolas de Psiquiatría. 33(1): 1–6.Google Scholar
Prieto, L., Sacristán, J.A., Hormaechea, J.A., Casado, A., Badia, X. and Gómez, J.C. (2004) Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Current Medical Research Opinion. 20(6): 827–835.CrossRefGoogle Scholar
Sánchez-Araña Moreno, T., Touriño Gonzalez, R., Hernández Fleta, J.L. and León Pérez, P. (2006). High prevalence of metabolic syndrome in schizophrenics patients: a review of the literature. Psiquiatría Biológica. 13(4): 127–135.CrossRefGoogle Scholar
Strassnig, M., Brar, J.S. and Ganguli, R. (2003) Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophrenia Research. 62(1–2): 73–76.CrossRefGoogle ScholarPubMed
Thakore, J.H. (2005) Metabolic syndrome and schizophrenia. British Journal of Psychiatry. 186: 455–456.CrossRefGoogle ScholarPubMed
von Hausswolff-Juhlin, Y., Bjartveit, M., Lindström, E. and Jones, P. (2009) Schizophrenia and physical health problems. Acta Psychiatrica Scandinavica. 119(s438): 15–21.CrossRefGoogle Scholar
WHOQOL Group (1993) Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Quality of Life Research. 2: 153–159.CrossRefGoogle Scholar
World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Geneva: WHO.Google Scholar